RxDoctor Payments Data

Sara Wemlinger, DO

Family Medicine · Palmetto, FLNPI 1609295245

Payments from drug & device makers

$2,599in general payments, 2019–2025

Across 112 payments — averaging $23.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$570
  • Novo Nordisk$291
  • Foundation Fusion Solutions, LLC$235
  • Amgen$221
  • Cardiovascular Systems Inc.$136
  • Janssen Scientific Affairs, LLC$123
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,599 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$25,623
Medicare patients
65
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban33$43,890
MounjaroTirzepatide34$39,039
FarxigaDapagliflozin Propanediol17$18,115
Fluticasone-SalmeterolFluticasone Propion/Salmeterol24$5,112
Albuterol Sulfate HfaAlbuterol Sulfate60$2,454
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,690
Rosuvastatin Calcium207$1,531
Atorvastatin Calcium195$1,400
Levothyroxine Sodium133$1,350
SynthroidLevothyroxine Sodium16$1,161
Losartan Potassium127$792
Gabapentin102$753
Duloxetine Hcl27$617
Lisinopril144$609
Omeprazole72$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$43,89033 claims
Lilly USA, LLCMounjaro$19$39,03934 claims
AstraZenecaFarxiga$101$18,11517 claims
AbbVieSynthroid$570$1,16116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palmetto

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →